Comparison of Administration Strategies of Ticagrelor in Patients With

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the differences in pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite depending on the strategy of the drug administration in patients with unstable angina pectoris.

Clinical Trial Description

On the basis of the current guidelines ticagrelor is a recommended antiplatelet agent in acute coronary syndromes, including unstable angina pectoris.

According to the results of the MOJITO study, performed in patients with ST-elevation myocardial infarction, the effect of ticagrelor, measured as platelet inhibition, may be achieved sooner when crushed tablets are administered. Thus, there may be significant differences in pharmacokinetics and pharmacodynamics of ticagrelor if pulverized drug is given orally or sublingually when compared with currently used oral administration of integral tablets.

The study is designed as an open-label, single-center, randomized trial of different strategies of administration of ticagrelor in patients with unstable angina pectoris. After enrollment, the participants will be randomized into three arms, each receiving ticagrelor. The drug will be given in: (1) pulverized tablets administered sublingually, (2) pulverized tablets administered orally or in (3) integral tablets orally. The time required for ticagrelor and its active metabolite AR-C124900XX to reach their maximum serum concentration will be measured as the primary outcome of the study. Moreover, further evaluation of other parameters including maximum plasma concentration and area under the plasma concentration of ticagrelor and its active metabolite will be assessed as secondary outcomes. The platelet reactivity will be measured with the Multiplate Analyzer. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02612116
Study type	Interventional
Source	Collegium Medicum w Bydgoszczy
Contact
Status	Completed
Phase	Phase 4
Start date	September 2015
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Active, not recruiting	`NCT02508714` - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents	N/A
Completed	`NCT02939248` - Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine	Phase 4
Active, not recruiting	`NCT02175706` - DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity	N/A
Completed	`NCT01377402` - ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study	N/A
Completed	`NCT00521976` - Risk Markers in the Acute Coronary Syndromes
Completed	`NCT02144090` - Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study	N/A
Completed	`NCT00627744` - Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction	Phase 4
Completed	`NCT00990262` - Rule Out Myocardial Infarction by Computer Assisted Tomography	N/A
Enrolling by invitation	`NCT04008173` - The International Survey of Acute Coronary Syndromes-ARCHIVES
Withdrawn	`NCT02165670` - BASIC VALIDATE Coronary Stent Registry
Completed	`NCT01293097` - Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI	Phase 4
Completed	`NCT01066650` - The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente	Phase 4
Completed	`NCT02747329` - A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT	N/A
Completed	`NCT02939235` - Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine	Phase 4
Not yet recruiting	`NCT03155971` - PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial)	N/A
Recruiting	`NCT04575207` - The Flash FFR Ⅱ Study	N/A
Terminated	`NCT02235753` - High-intensity Exercise After Acute Cardiac Event (HITCARE)	N/A
Completed	`NCT02007187` - Danhong Injection in the Treatment of Unstable Angina Pectoris	Phase 4
Completed	`NCT01752582` - BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms